{"entity":{"id":"imnn-201","kind":"drug","name":"IMNN-201","aka":[],"tldr":"IMNN-201 is an experimental DNA plasmid cancer vaccine from Imunon, in preclinical development for melanoma.","summary":"IMNN-201 is a DNA plasmid cancer vaccine (FixPlas platform) from Imunon. A plasmid DNA vaccine against the tumour-associated antigen Trp2. Its furthest stage is preclinical development, for melanoma. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"Imunon: imunon.com","url":"https://imunon.com/pipeline/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["imunon"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"IMNN-201","modality":"DNA plasmid cancer vaccine (FixPlas platform)","mechanism":"A plasmid DNA vaccine against the tumour-associated antigen Trp2.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/imnn-201/","neighbours":{"company":[{"id":"imunon","kind":"company","name":"Imunon","route":"/companies/imunon/"}]}}